Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00182806 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: gemcitabine hydrochloride
DRUG: irinotecan hydrochloride

Sponsor

Roswell Park Cancer Institute